Date: 4/22/2021
Your Name: Yan Jiang
Manuscript Title: DAPK2 activates NF-κB through autophagy-dependent degradation of I-κBα during thyroid cancer
development and progression
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	∕None	
4	Consulting fees	<u>√</u> None	

_	December to the control of the	/Alara	
5	Payment or honoraria for	✓None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
	meetings and, or traver		
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
10	in other board, society,	<u></u>	
	committee or advocacy		
	•		
4.4	group, paid or unpaid	(2)	
11	Stock or stock options	√ None	
12	Receipt of equipment,	✓None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	✓None	
	financial interests		

Yan Jiang has nothing to disclose.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 4/22/2021
Your Name: Ji Liu
Manuscript Title:DAPK2 activates NF-κB through autophagy-dependent degradation of I-κBα during thyroid cancer
development and progression
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>√</u> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time innit for this item.		
		Time frame: past	26 months
2	Grants or contracts from	✓ None	50 months
	any entity (if not indicated	None	
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	_ <u>√</u> None	
	_		

5	Payment or honoraria for	<u>√</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
7	Support for attending meetings and/or travel	<u>√</u> None	
	and the second s		
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	✓None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>√</u> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓None	
12	Receipt of equipment,	✓None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	✓None	
	financial interests		

Ji Liu has nothing to disclose.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 4/22/2021
Your Name: Hua Xu
Manuscript Title: DAPK2 activates NF-κB through autophagy-dependent degradation of I-κBα during thyroid cancer
development and progression
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>√</u> None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	√ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>√</u> None	
4	Consulting fees	<u>√</u> None	

		1	
5	Payment or honoraria for	✓None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
		(1)	
6	Payment for expert	<u>√</u> None	
	testimony		
7	Support for attending	✓None	
	meetings and/or travel		
8	Patents planned, issued or	√None	
	pending		
	periamb		
•	5 5 .	(N)	
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>√</u> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
11	Stock of Stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		
	inianistal litterests		

Hua Xu has nothing to disclose.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 4/22/2021
Your Name: Xiao Zhou
Manuscript Title: <u>DAPK2 activates NF-κB through autophagy-dependent degradation of I-κBα during thyroid cancer</u>
development and progression
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>√</u> None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	√ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>√</u> None	
4	Consulting fees	<u>√</u> None	

_	December to the control of the	/Alara	
5	Payment or honoraria for	✓None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
	meetings and, or traver		
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
10	in other board, society,	<u></u>	
	committee or advocacy		
	•		
4.4	group, paid or unpaid	(2)	
11	Stock or stock options	√ None	
12	Receipt of equipment,	✓None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	✓None	
	financial interests		

Xiao Zhou has nothing to disclose.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 4/22/2021
Your Name: Liu He
Manuscript Title: <u>DAPK2 activates NF-κB through autophagy-dependent degradation of I-κBα during thyroid cancer</u>
development and progression
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>√</u> None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	√ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>√</u> None	
4	Consulting fees	<u>√</u> None	

5	Payment or honoraria for	∕ None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
_	C	(a)	
7	Support for attending meetings and/or travel	<u>√</u> None	
	meetings and, or traver		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data	✓None	
	Safety Monitoring Board or		
10	Advisory Board	_ <u>√</u> None	
10	Leadership or fiduciary role in other board, society,	<u>v</u> none	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
12	Descipt of onvigenment	√None	
12	Receipt of equipment, materials, drugs, medical	vivone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	✓None	

Liu He has nothing to disclose.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 4/22/2021	
Your Name: Chenfang Zhu	
Manuscript Title: DAPK2 activates NF-κB through autophagy-dependent degradation of I-κBα during thyroid	ancer
development and progression	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>√</u> None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	√ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>√</u> None	
4	Consulting fees	<u>√</u> None	

_	December to the control of the	/Alara	
5	Payment or honoraria for	✓None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>√</u> None	
	testimony		
7	Support for attending	√None	
	meetings and/or travel		
	meetings and, or traver		
8	Patents planned, issued or	<u>√</u> None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
10	in other board, society,	<u></u>	
	committee or advocacy		
	•		
4.4	group, paid or unpaid	(2)	
11	Stock or stock options	√ None	
12	Receipt of equipment,	✓None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	✓None	
	financial interests		

Chenfang Zhu has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement: